Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis.

ABSTRACT:

Background

With the advent of asparaginase-based drugs, patients with natural killer/T-cell lymphoma (NKTCL) have achieved excellent efficacy. However, the prognosis is poor in patients with advanced disease, and even worse in relapse/refractory patients. This meta-analysis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination treatment strategies in patients with NKTCL.

Method

Seven databases were extensively searched from inception to November 2023 and updated in April 2024, with no language restrictions. The pooled overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs) were calculated via a random effects model. Heterogeneity was tested utilizing the I-square (I

SUBMITTER: Yang J 

PROVIDER: S-EPMC11874407 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature